Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00942331 · FLOW

Participant flow

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer · Source last updated 2026-06-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm II (GCB)
  2. description
    Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG001
    title
    Arm I (GCP)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        15
      2. group Id
        FG001
        num Subjects
        22
      type
      Did not start treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        252
      2. group Id
        FG001
        num Subjects
        254
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        237
      2. group Id
        FG001
        num Subjects
        232
      comment
      Started treatment
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        15
      2. group Id
        FG001
        num Subjects
        22
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm II (GCB)
  2. description
    Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG001
    title
    Arm I (GCP)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        15
      2. group Id
        FG001
        num Subjects
        22
      type
      Did not start treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        252
      2. group Id
        FG001
        num Subjects
        254
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        237
      2. group Id
        FG001
        num Subjects
        232
      comment
      Started treatment
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        15
      2. group Id
        FG001
        num Subjects
        22
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice